Milberg LLP is currently investigating the proposed acquisition of Optimer Pharmaceuticals, Inc. (“Optimer”) (NasdaqGS: OPTR) by Cubist Pharmaceuticals, Inc. (“Cubist”), as being potentially unfair to Optimer’s public shareholders.
On July 30, 2013, Optimer announced that they signed a merger agreement pursuant to which Cubist will acquire all of the outstanding shares of Optimer common stock for $10.75 per share in cash, or approximately $535 million on a fully diluted basis. Optimer stockholders will also receive a Contingent Value Right (CVR), which is expected to be publicly traded, entitling the holder to receive an additional one-time cash payment of up to $5.00 for each share they own if certain net sales of DIFICID®(fidaxomicin) are achieved, or a total or total transaction value of up to $801 million on a fully diluted basis. The transaction has been approved by the boards of directors of both companies.
Even if the DEFICID sales target is achieved, the resulting total consideration of $15.75 would still be 10% below analysts’ $17.50 mean target price and 6.3% lower than Optimer’s recent 52-week high of $16.80 on May 15, 2013.
Milberg’s investigation primarily concerns the potential unfairness of the consideration being provided to Optimer shareholders and possible conflicts of interest of Optimer’s senior management.Persons with relevant information, and Optimer shareholders with questions about this investigation, are invited to fill out the form on the right, contact our Firm by calling 866.582.8140, or contacting the Milberg LLP attorneys listed below. Kent A. BronsonMilberg LLPOne Pennsylvania Plaza, 49th Fl.New York, NY 10119-0165(212) 594-5300 email@example.com Gloria Kui MelwaniMilberg LLPOne Pennsylvania Plaza, 49th Fl.New York, NY 10119-0165(212) 594-5300 firstname.lastname@example.org Milberg LLP has been representing consumers and investors for more than four decades and serves as lead counsel in federal and state courts throughout the United States. Attorney Advertising. Prior Results Do Not Guarantee A Similar Outcome.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts